The administration of Clenbuterol or any other beta2-agonist will be banned within 120 days of a race at the 2021-22 Oaklawn Park meet, Oaklawn announced Thursday. The rule, agreed to in partnership with the Arkansas HBPA and Arkansas Racing Commission, extends the ban from 60 days, which was the standard for last season's meet.
Conducted by Industrial Labs, the presence of Clenbuterol and other beta2-agonist will be determined through blood, urine and hair follicle testing.
“Banning the use of Clenbuterol and other beta2-agonists further proves our commitment to the safety and integrity of our racing program,” said Oaklawn President Louis Cella. “Every decision we make is to enhance the experience of our horsemen and fans at Oaklawn. When we say “Racing First,' we lead by example.”
Oaklawn's 2021-2022 season runs from Friday, Dec. 3 to Sunday, May 8.